These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 29799328)

  • 21. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
    Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
    Villa G; Hernández-Pastor LJ
    BMC Cancer; 2013 Sep; 13():399. PubMed ID: 24004638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
    Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
    BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
    Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
    Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Perez JR; Agarwal N; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):e573-e582. PubMed ID: 28139444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
    Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
    J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 31. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.
    Guo A; Niyazov A; Macaulay D; Terasawa E; Schmerold L; Wu EQ; Krieger S
    J Manag Care Spec Pharm; 2017 Jul; 23(7):771-780. PubMed ID: 28650249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
    Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
    J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
    Yi E; Dai D; Piao OW; Zheng JZ; Park Y
    J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib.
    MacLean EA; Sandin R; Mardekian J
    J Manag Care Spec Pharm; 2015 Sep; 21(9):841-3. PubMed ID: 26308231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.